Skip to NavigationSkip to content

Taisho Pharma to buy Bristol-Myers Squibb's consumer health business in deal worth $1.6 bn

Published on 19/12/18 at 05:23pm

Japanese company Taisho Pharmaceuticals has offered Bristol-Myers Squibb $1.6 billion for its UPSA consumer health business.

With more than a century’s worth of experience, Taisho, the largest over-the-counter drugmaker in Japan, was established in 1912. The two companies have an established relationship with Taisho having purchased PT Squibb Indonesia from BMS in 2009.

Founded in 1935, BMS’ UPSA consumer health business develops and delivers pharmaceutical drugs and supplements for everyday ailments, covering a wide range of therapeutic areas which include: pain, cough & cold, vitamins and supplements, gastrointestinal and sleep.

“Today’s announcement marks the culmination of an in-depth strategic review to identify the best option to grow the UPSA business for the long-term,” said Giovanni Caforio, chairman and chief executive officer of Bristol-Myers Squibb.”

“UPSA is a strong business that deserves the best possible opportunities for its employees and its future development. With Taisho we have found an experienced and reliable buyer with the strategic interest to successfully sustain and grow the business for the future.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches